DDC
BMRN icon

DF Dent & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

DF Dent & Co’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,110
Closed -$219K – 178
2013
Q4 		$219K Buy
+3,110
New +$211K 0.01% 236

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $29.1B AUM 43.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

DF Dent & Co's BMRN Position: Q1 2014 in Review

DF Dent & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2014, closing a stake of 3,110 shares — an estimated $219K sold.

DF Dent & Co first reported a position in BMRN in Q4 2013 and held it in 1 quarter. The position peaked at $219K in Q4 2013. 313 funds tracked by Wall St. Rank hold BMRN as of Q1 2014.

  • DF Dent & Co reported no remaining BioMarin Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • DF Dent & Co sold 3,110 BioMarin Pharmaceuticals shares in Q1 2014, an estimated $219K.
  • DF Dent & Co first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • DF Dent & Co's BioMarin Pharmaceuticals position peaked at $219K in Q4 2013.
  • 313 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2014.

Based on DF Dent & Co's 13F filing for Q1 2014, filed 16 Apr 2014.